MedPath

Dihydroartemisinin–Piperaquine versus Sulfadoxine–Pyrimethamine Use for the Prevention of Malaria during Pregnancy

Not Applicable
Conditions
Malaria
Registration Number
PACTR202002644579177
Lead Sponsor
Royal Society of Tropical Medicine and Hygiene
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
Female
Target Recruitment
250
Inclusion Criteria

•Pregnant women aged 15-49 years
•Attending antenatal clinic (ANC) for the first time in this current pregnancy
•Gestation of 16-20 weeks (as assessed by LMP and/or ultra-scan)
•HIV-negative pregnant women
•No current history of receiving IPTp-SP
•Willing to provide informed written consent
•Planning to stay in Maiduguri and attending ANC and have child delivery at University of Maiduguri Teaching Hospital, Maiduguri

Exclusion Criteria

•A history of allergic reaction to sulfa drugs (SP or cotrimoxazole) or DP
•Having haemoglobin level < 7 g/dl
•Positive test for falciparum malaria
•History of receipt of antimalarials or antibiotics with antimalarial activity (cotrimoxazole, rifampin, doxycycline, clindamycin, tetracycline, erythromycin, azithromycin, chloramphenicol) in the past month
•Women with sickle cell disease
•Women with high-risk pregnancies (presence of high blood pressure and diabetes)
•HIV- Positive women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath